Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called CDK4/6 inhibitors.

Three CDK4/6 inhibitors are now approved, clinically established, and available in India — Palbociclib (Palbace), Ribociclib (Kryxana), and Abemaciclib (Ramiven). Each has a substantial Phase 3 evidence base, each is used in combination with endocrine therapy, and each has demonstrated clinically meaningful improvements in progression-free survival. But they are not interchangeable. Subtle and not-so-subtle differences in efficacy data, safety profiles, dosing, and approved indications mean the choice between them has clinical significance — particularly in 2026, when all three are fully integrated into Indian oncology practice and the question is not whether to use a CDK4/6 inhibitor but which one and when.

This article is a practical guide for Indian oncologists and patients navigating that choice.

What CDK4/6 Inhibitors Actually Do

Before comparing the three agents, it helps to understand why this class of medicines works so well in HR+/HER2- breast cancer.

CDK4 and CDK6 are cyclin-dependent kinases — enzymes that drive the transition from G1 to S phase in the cell cycle, the point at which a cell commits to DNA replication and division. In HR+/HER2- breast cancer, estrogen receptor signalling continuously activates CDK4/6 via cyclin D1 upregulation — driving relentless cancer cell proliferation.

Endocrine therapy (aromatase inhibitors, Fulvestrant) reduces the estrogen signal that activates this pathway. CDK4/6 inhibitors block the pathway directly — preventing Rb phosphorylation, arresting the cell cycle at G1, and inducing cancer cell senescence. The combination addresses both the upstream signal (endocrine therapy) and the downstream effector (CDK4/6 inhibitors) simultaneously — which is why the combination consistently outperforms endocrine therapy alone.

A comprehensive review published in Oncology Reports in March 2026 confirmed all three approved CDK4/6 inhibitors demonstrate significant improvements in progression-free survival when combined with endocrine therapy in HR+/HER2- breast cancer. However, as Nature Reviews Clinical Oncology noted in May 2026, resistance mechanisms remain a primary clinical challenge — which makes the choice of initial CDK4/6 inhibitor and the sequencing of subsequent therapy increasingly important.

The Three Agents — Evidence, Differences, and India Availability

Palbociclib — Palbace — 75mg, 100mg, 125mg Capsules

Palbociclib was the first CDK4/6 inhibitor approved — FDA approval in 2015 — and carries the longest clinical follow-up data of any agent in this class. The PALOMA-2 trial demonstrated significant PFS improvement vs Letrozole alone in first-line metastatic HR+/HER2- breast cancer, and PALOMA-3 established efficacy after prior endocrine therapy with Fulvestrant.

In 2026, Palbociclib remains the most widely prescribed CDK4/6 inhibitor in India — partly due to the availability of generic versions at accessible pricing, and partly due to the depth of prescriber familiarity built over a decade of clinical use.

Key characteristics:

• Dose: 125mg once daily, 21 days on / 7 days off
• Partner: Aromatase inhibitor (Arimidex, Letrozole) first-line or Fulvestrant (Faslodex) after prior endocrine therapy
• PFS benefit: Significant vs endocrine therapy alone across all PALOMA trials
• OS benefit: Not significantly demonstrated in Phase 3 — an important distinction vs Ribociclib and Abemaciclib
• Neutropenia: Most common Grade 3-4 adverse event (~66%) — requires CBC monitoring but rarely causes serious infection
• No continuous dosing — the 7-day break distinguishes Palbociclib from Abemaciclib

Ribociclib — Kryxana — 200mg Tablets

Ribociclib has the strongest overall survival data of the three CDK4/6 inhibitors — and this distinction is clinically significant. The MONALEESA-2 trial demonstrated significant OS benefit with Ribociclib + Letrozole in first-line postmenopausal metastatic breast cancer — a 12.4-month improvement in median OS. MONALEESA-7 demonstrated OS benefit in premenopausal patients with ovarian suppression — the first CDK4/6 inhibitor trial to show this specifically in premenopausal women. MONALEESA-3 demonstrated OS benefit with Ribociclib + Fulvestrant.

This consistent OS benefit across three Phase 3 trials in different patient populations makes Ribociclib the CDK4/6 inhibitor with the most robust survival evidence.

Key characteristics:

• Dose: 600mg once daily, 21 days on / 7 days off (3 tablets of 200mg)
• Partner: Aromatase inhibitor or Faslodex (Fulvestrant) — valid in premenopausal patients with ovarian suppression (Zoladex/Goserelin)
• OS benefit: Significant across MONALEESA-2, -3, and -7
• QTc prolongation: Mandatory ECG monitoring at baseline, 2 weeks, and 4 weeks. Avoid in patients with pre-existing QTc prolongation
• Hepatotoxicity: Monitor LFTs — Grade 3-4 ALT/AST elevation in approximately 9%
• Premenopausal indication: Uniquely validated in MONALEESA-7

Abemaciclib — Ramiven — 50mg, 100mg, 150mg, 200mg Tablets

Abemaciclib is the most structurally distinctive of the three CDK4/6 inhibitors. It is the only CDK4/6 inhibitor approved for continuous twice-daily dosing (no off-week), it can be used as monotherapy in certain heavily pretreated patients, and it is the only CDK4/6 inhibitor approved for adjuvant use in high-risk early breast cancer.

MONARCH 2 demonstrated OS benefit with Abemaciclib + Fulvestrant in second-line metastatic HR+/HER2- breast cancer. The monarchE trial established Abemaciclib + endocrine therapy as adjuvant treatment for high-risk HR+/HER2- node-positive early breast cancer — with sustained benefit at 5 years.

Key characteristics:

• Dose: 150mg twice daily continuously (no off-week) — metastatic; 150mg twice daily for 2 years — adjuvant (monarchE)
• Partner: Aromatase inhibitor first-line; Fulvestrant second-line; endocrine therapy adjuvant
• OS benefit: Significant in MONARCH 2 (second-line metastatic with Fulvestrant)
• Diarrhoea: Most common and distinguishing side effect (~85% any grade, ~13% Grade 3) — prophylactic Loperamide at treatment initiation is standard
• Adjuvant indication: The only CDK4/6 inhibitor approved for early breast cancer adjuvant use
• Monotherapy option: Approved in heavily pretreated metastatic HR+/HER2- breast cancer

Head-to-Head Comparison

Which Patients Benefit Most From Each Agent

Choose Palbociclib (Palbace) when:

• Cost accessibility is the primary consideration
• First-line postmenopausal HR+/HER2- metastatic breast cancer with Letrozole or Anastrozole
• Patients where QTc monitoring infrastructure is limited
• Established prescriber familiarity preferred

Choose Ribociclib (Kryxana) when:

• Overall survival benefit is the priority — MONALEESA data is the most consistent
• Premenopausal patients requiring CDK4/6 inhibitor + ovarian suppression (Zoladex) — MONALEESA-7 validated this specifically
• Both first-line (with AI) and second-line (with Faslodex) settings

Choose Abemaciclib (Ramiven) when:

• High-risk early breast cancer — node-positive HR+/HER2- — adjuvant use per monarchE
• Second-line metastatic with Faslodex — MONARCH 2 OS benefit
• Heavily pretreated metastatic patients where monotherapy is being considered
• Patients where neutropenia avoidance is a priority

CDK4/6 Inhibitors and PIK3CA Mutations — When to Add Alpelisib

For patients who progress on CDK4/6 inhibitor + endocrine therapy and have a PIK3CA mutation confirmed by NGS, Pivikto (Alpelisib) + Faslodex (Fulvestrant) is a validated next-line option — demonstrated in the BYLieve trial which specifically enrolled post-CDK4/6i patients. PIK3CA testing at diagnosis or at progression is therefore increasingly important in Indian oncology practice.

Pre-Treatment Considerations Specific to India

Confirm menopausal status before selecting aromatase inhibitor combinations. Aromatase inhibitors are ineffective in premenopausal women without ovarian suppression. For premenopausal patients, Ribociclib + Zoladex (Goserelin) + AI or Fulvestrant has the strongest evidence from MONALEESA-7.

QTc monitoring for Ribociclib. Baseline ECG and ECG at weeks 2 and 4 required. In centres where ECG access between consultations is limited, Palbociclib or Abemaciclib may be more practical.

Diarrhoea management for Abemaciclib. Prophylactic Loperamide at treatment initiation significantly reduces Grade 3-4 severity. Patient counselling before starting is essential.

PIK3CA testing — plan ahead. India’s oncology infrastructure is expanding rapidly — Metropolis Healthcare’s Centre of Genomics opened in February 2026 specifically to accelerate personalised cancer diagnostics. Tissue NGS or plasma liquid biopsy for PIK3CA status should be incorporated at diagnosis — not only at progression.

Managing CDK4/6 Inhibitor Side Effects

Neutropenia (Palbociclib and Ribociclib): Grade 3-4 in ~60-66%. Febrile neutropenia is uncommon (<2%) — uncomplicated neutropenia without fever does not require dose reduction on first occurrence. CBC every 2 weeks for first 2 cycles, then monthly.

Diarrhoea (Abemaciclib): Start Loperamide 4mg at first loose stool. Dietary modification in first month. Grade 3+ — hold Abemaciclib; restart at reduced dose when resolved to Grade 1.

QTc prolongation (Ribociclib): Baseline ECG. Correct electrolytes before starting. Avoid concomitant QTc-prolonging medicines including ondansetron, domperidone, antifungals. Withhold for QTc >480ms.

Hepatotoxicity (all three): LFTs at baseline, every 2 weeks for first 2 cycles, then monthly. Withhold for Grade 3; permanently discontinue for Grade 4.

A.K. Pharma — Pharmaceutical Distributor in Delhi for the Complete Breast Cancer Portfolio

A.K. Pharma is a licensed medicine distributor and pharmaceutical distributor in Delhi supplying the complete HR+/HER2- breast cancer targeted therapy portfolio — all three CDK4/6 inhibitors, their endocrine therapy partners, and the post-CDK4/6i options — to hospitals, oncology centres, and pharmacies across India.

CDK4/6 Inhibitors:

• Palbace (Palbociclib) — 75mg, 100mg, 125mg capsules
• Kryxana (Ribociclib) — 200mg tablets
• Ramiven (Abemaciclib) — 50mg, 100mg, 150mg, 200mg tablets

Endocrine Therapy Partners:

• Arimidex (Anastrozole) — aromatase inhibitor
• Aromasin (Exemestane) — aromatase inhibitor
• Faslodex (Fulvestrant) — SERD
• Zoladex (Goserelin) — GnRH agonist for premenopausal OFS

Post-CDK4/6i Options:

• Pivikto (Alpelisib) — PI3Kα inhibitor for PIK3CA-mutated HR+/HER2- metastatic breast cancer

Browse our complete cancer medicines or contact us directly.

📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052

📞 011 4172 6999

📱 WhatsApp: +91 9810034827

🌐 akpharma.in

Frequently Asked Questions